{"Clinical Trial ID": "NCT00118157", "Intervention": ["INTERVENTION 1:", "1st arm", "Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28.", "Lapatinib ditosylate: oral", "Tamoxifen citrate: oral"], "Eligibility": ["Incorporation criteria:", "\u2022 Primary adenocarcinoma of the breast confirmed by histology or cytology", "A locally advanced or metastatic disease that does not lend itself to surgery or radiation therapy with curative intent", "Positive cancer of estrogen and/or progesterone receptor", "Patients failed hormonal manipulation with tamoxifen, either without response (primary resistance) to initial treatment or with relapse/progress after an initial response (secondary failure)", "At least 1 measurable (target) lesion (i.e., any malignant tumour mass that can be accurately measured in at least 1 dimension, >= 20 mm with conventional radiographic techniques, or >= 10 mm with magnetic resonance imaging [MRI] or computer spiral tomography [CT]), in a previously unirradiated area", "Not more than 450 mg/m2 of anterior doxorubicin", "Life expectancy >= 3 months", "= < 2 (Karnofsky >= 60%)", "Absolute number of neutrophils (ANC) >= 1500/mm^3", "Platelets >= 100 000/mm^3", "Hemoglobin >= 9.0 g/dL", "Creatinine (Cr) = < upper limit of normal (ULN) or Cr clearance > 60 mL/min/m^2", "Total bilirubin = < 1.5 x ULN", "Alanine aminotransferase (ALT) = < 1.5 x ULN or = < 3 x ULN with liver metastases", "Aspartate aminotransferase (AST) = < 5 x ULN or = < 3 x ULN with liver metastases", "The fraction of cardiac ejection in the institutional range of normal measured by echocardiogram or multi-channel acquisition scan (MUGA); (note that reference and treatment scans should be performed in the same mode and preferably in the same institution)", "Patients on oral anticoagulants (Coumadin, warfarin) should either be switched to low molecular weight heparin or should be subject to very close monitoring of the International Standard Report (INR), if Coumadin treatment is continued.", "A negative serum pregnancy test within 7 days of registration in premenopausal women and women within 6 months of menopause; if a woman becomes pregnant or suspects that she is pregnant while participating in this study, she should immediately inform her attending physician; men and women should be advised about the use of contraceptives because of the unknown effects of the medication on the fetus and breast-feeding should be avoided.", "Capacity to understand and willingness to sign a written informed consent document", "\u2022 Ability to swallow and store oral medicines", "- Exclusion criteria:", "Patients who have previously received EGFR and/or Her-2 therapy targeting treatment (prior trastuzumab combined with adjuvant chemotherapy is allowed, but combination of trastuzumab with hormonal therapy is not allowed)", "Current treatment with any other antineoplastic agent, including trastuzumab; patients may continue to receive zoledronic acid for bone metastases or hypercalcaemia.", "\u2022 Radiotherapy within 2 weeks of registration or surgery within 4 weeks", "(patients with asymptomatic, stable metastases already treated in the central nervous system and surrounding tissues are eligible; however, patients should not need corticosteroids due to central nervous system metastases at the time of entry into the study)", "One of the following conditions within 6 months of registration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, coronary/peripheral bypass; patients with pulmonary embolism, deep venous thrombosis or other clinically significant thromboembolic event within 6 months of registration are eligible if clinically stable during anticoagulant treatment", "\u2022 Pregnancy or breast-feeding; breast-feeding should be discontinued if the mother is treated with GW572016; patients should agree to use effective contraception during the study period, be surgically sterile or post-menopausal; and male patients should use effective contraception during the study period or be surgically sterile; the definition of effective contraception should be based on the judgement of the investigator.", "Patients with human immunodeficiency virus (HIV) receiving combined antiretroviral therapy are excluded from the study.", "History of allergic reactions attributed to compounds of chemical or biological composition similar to GW572016", "* Patients with gastrointestinal disease (GI) resulting in inability to take oral medication, malabsorption syndrome, need for intravenous feeding (IV), previous surgical procedures affecting absorption or uncontrolled IG inflammatory disease (e.g. Crohn ulcerative colitis)", "The treatment with all agents interacting with cytochrome P450 3A should be avoided and used with caution, if necessary; patients should be replaced with other medicinal products where possible; patients requiring anticoagulation should either be replaced by a low molecular weight heparin injection or should be closely monitored for INR if Coumadin is continued.", "Previous (within 5 years of listing) or current malignancies at other sites, with the exception of skin cancers of adequately treated basal or squamous cells and in situ cervix carcinomas", "Other acute or chronic serious medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with participating in the study or administration of drugs in the study or that may interfere with the interpretation of the results of the study and, in the opinion of the investigator, render the patient inappropriate for entry into the study"], "Results": ["Performance measures:", "\u25cf Response rate of tumours (complete and partial) assessed by solid tumour response evaluation criteria (RECIST)", "[Unspecified]", "Duration: 4 weeks", "Results 1:", "Title of arm/group: Arm 1", "Description of the arm/group: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28.", "Lapatinib ditosylate: oral", "Tamoxifen citrate: oral", "Total number of participants analysed: 17", "Type of measurement: Number", "Unit of measurement: participants 1 (1-27)"], "Adverse Events": ["Undesirable Events 1:", "Total: 19/19 (100.00 per cent)", "Haemolysis 3/19 (15.79%)", "1/19 (5.26%)", "1/19 (5.26%)", "- Heart disorders - Other, specify 4/19 (21.05%)", "1/19 (5.26%)", "Diarrhoea 19/19 (100.00 per cent)", "Death NOS 10/19 (52.63 %)", "Fatigue 13/19 (68.42 per cent)", "3/19 (15.79%)", "Dehydration 1/19 (5.26%)"]}